# Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

> **NCT00766337** · PHASE2 · TERMINATED · sponsor: **Santen Inc.** · enrollment: 62 (actual)

## Conditions studied

- Age-Related Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Sirolimus in combination with ranibizumab
- **DRUG:** Sirolimus in combination with ranibizumab
- **DRUG:** Placebo in combination with ranibizumab

## Key facts

- **NCT ID:** NCT00766337
- **Lead sponsor:** Santen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2009-11
- **Final completion:** 2010-03
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2013-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00766337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00766337, "Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00766337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*